ONTX
Closed
Onconova Therapeutics Inc
0.6642
-7.2658 (-91.62%)
Last Update: 01 May 2024 16:30:00
Yesterday: 7.93
Day's Range: 0.64 - 0.669
Send
sign up or login to leave a comment!
When Written:
0.7
Onconova Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel drugs for the treatment of cancer. The company's lead product candidate, rigosertib, is a small molecule inhibitor of cellular signaling pathways that are frequently deregulated in cancer cells. Rigosertib is being developed for the treatment of several types of cancer, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and solid tumors.
Onconova was founded in 1998 and is headquartered in Newtown, Pennsylvania. The company's research and development efforts are focused on identifying and developing new compounds that target specific pathways involved in cancer growth and progression. Onconova has partnerships with several pharmaceutical companies, including Baxter International, Inc., and SymBio Pharmaceuticals, Ltd.
In addition to rigosertib, Onconova has a pipeline of other drug candidates in various stages of development for the treatment of cancer. The company is committed to advancing the science of cancer treatment and improving the lives of patients with cancer.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Onconova was founded in 1998 and is headquartered in Newtown, Pennsylvania. The company's research and development efforts are focused on identifying and developing new compounds that target specific pathways involved in cancer growth and progression. Onconova has partnerships with several pharmaceutical companies, including Baxter International, Inc., and SymBio Pharmaceuticals, Ltd.
In addition to rigosertib, Onconova has a pipeline of other drug candidates in various stages of development for the treatment of cancer. The company is committed to advancing the science of cancer treatment and improving the lives of patients with cancer.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
0.7
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of cancer. The company is based in Newtown, Pennsylvania, and was founded in 1998.
Onconova's lead drug candidate is rigosertib, a small molecule inhibitor that targets the signaling pathways involved in cancer cell growth and survival. Rigosertib is currently being evaluated in clinical trials for the treatment of various types of cancer, including myelodysplastic syndromes, acute myeloid leukemia, and solid tumors.
In addition to rigosertib, Onconova is also developing other drug candidates, including ON 123300, a dual inhibitor of CDK4/6 and ARK5, and ON 150030, a small molecule inhibitor of the Wnt/beta-catenin pathway.
Onconova has partnerships with several pharmaceutical companies, including HanX Biopharmaceuticals, Pint Pharma, and Inceptua Medicines Access, to help develop and commercialize its drug candidates globally.
Overall, Onconova Therapeutics Inc is committed to advancing innovative therapies for the treatment of cancer and improving the lives of patients affected by this disease.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Onconova's lead drug candidate is rigosertib, a small molecule inhibitor that targets the signaling pathways involved in cancer cell growth and survival. Rigosertib is currently being evaluated in clinical trials for the treatment of various types of cancer, including myelodysplastic syndromes, acute myeloid leukemia, and solid tumors.
In addition to rigosertib, Onconova is also developing other drug candidates, including ON 123300, a dual inhibitor of CDK4/6 and ARK5, and ON 150030, a small molecule inhibitor of the Wnt/beta-catenin pathway.
Onconova has partnerships with several pharmaceutical companies, including HanX Biopharmaceuticals, Pint Pharma, and Inceptua Medicines Access, to help develop and commercialize its drug candidates globally.
Overall, Onconova Therapeutics Inc is committed to advancing innovative therapies for the treatment of cancer and improving the lives of patients affected by this disease.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!